Simplex Trading’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-14,791
| Closed | -$87.8K | – | 9689 |
|
|
2025
Q2 | $78K | Buy |
14,791
+13,516
| +1,060% | +$79.8K | ﹤0.01% | 5474 |
|
|
2025
Q1 | $11K | Sell |
1,275
-206
| -14% | -$2.47K | ﹤0.01% | 7041 |
|
|
2024
Q4 | $20K | Buy |
+1,481
| New | +$27.3K | ﹤0.01% | 6690 |
|
|
2024
Q3 | – | Sell |
-1,985
| Closed | -$53.7K | – | 9183 |
|
|
2024
Q2 | $48K | Buy |
+1,985
| New | +$43.6K | ﹤0.01% | 6139 |
|
|
2024
Q1 | – | Sell |
-412
| Closed | -$8.86K | – | 9494 |
|
|
2023
Q4 | $7K | Sell |
412
-4,454
| -92% | -$77.1K | ﹤0.01% | 7679 |
|
|
2023
Q3 | $78K | Sell |
4,866
-40,521
| -89% | -$771K | ﹤0.01% | 5354 |
|
|
2023
Q2 | $1.05M | Buy |
45,387
+28,685
| +172% | +$626K | ﹤0.01% | 2548 |
|
|
2023
Q1 | $387K | Buy |
16,702
+16,613
| +18,666% | +$337K | ﹤0.01% | 3543 |
|
|
2022
Q4 | $1K | Buy |
+89
| New | +$1.66K | ﹤0.01% | 8867 |
|
|
2022
Q1 | – | Sell |
-4,782
| Closed | -$122K | – | 11052 |
|
|
2021
Q4 | $131K | Buy |
4,782
+2,305
| +93% | +$66.8K | ﹤0.01% | 5818 |
|
|
2021
Q3 | $77K | Sell |
2,477
-700
| -22% | -$23.2K | ﹤0.01% | 6976 |
|
|
2021
Q2 | $97K | Buy |
3,177
+2,712
| +583% | +$78.4K | ﹤0.01% | 6771 |
|
|
2021
Q1 | $14K | Sell |
465
-2,730
| -85% | -$77.5K | ﹤0.01% | 7708 |
|
|
2020
Q4 | $63K | Buy |
+3,195
| New | +$51.6K | ﹤0.01% | 5926 |
|
|
2020
Q1 | – | Sell |
-10,518
| Closed | -$222K | – | 8017 |
|
|
2019
Q4 | $286K | Buy |
10,518
+6,035
| +135% | +$166K | ﹤0.01% | 3339 |
|
|
2019
Q3 | $128K | Sell |
4,483
-9,693
| -68% | -$282K | ﹤0.01% | 4053 |
|
|
2019
Q2 | $393K | Sell |
14,176
-2,788
| -16% | -$78.7K | ﹤0.01% | 2814 |
|
|
2019
Q1 | $563K | Buy |
+16,964
| New | +$516K | ﹤0.01% | 2532 |
|
|
2018
Q3 | – | Sell |
-2,126
| Closed | -$94.5K | – | 7812 |
|
|
2018
Q2 | $79K | Buy |
2,126
+1,747
| +461% | +$59K | ﹤0.01% | 4550 |
|
|
2018
Q1 | $11K | Buy |
+379
| New | +$12.8K | ﹤0.01% | 3961 |
|
|
2017
Q4 | – | Sell |
-8,244
| Closed | -$278K | – | 6420 |
|
|
2017
Q3 | $298K | Sell |
8,244
-35,695
| -81% | -$1.02M | 0.01% | 959 |
|
|
2017
Q2 | $1.14M | Buy |
43,939
+24,701
| +128% | +$524K | 0.05% | 320 |
|
|
2017
Q1 | $369K | Buy |
19,238
+15,106
| +366% | +$268K | 0.02% | 849 |
|
|
2016
Q4 | $68K | Buy |
4,132
+385
| +10% | +$6.97K | ﹤0.01% | 1856 |
|
|
2016
Q3 | $77K | Buy |
3,747
+156
| +4% | +$3.96K | 0.01% | 1745 |
|
|
2016
Q2 | $109K | Buy |
+3,591
| New | +$125K | 0.01% | 1414 |
|
Other funds holding MYGN
O
GCM
VCM
VPM
Simplex Trading's MYGN Position: Q3 2025 in Review
Simplex Trading sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 14,791 shares — an estimated $87.8K sold.
Simplex Trading first reported a position in MYGN in Q2 2016 and held it in 26 quarters. The position peaked at $1.14M in Q2 2017. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.
- Simplex Trading reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
- Simplex Trading sold 14,791 Myriad Genetics shares in Q3 2025, an estimated $87.8K.
- Simplex Trading first reported a position in Myriad Genetics in Q2 2016 and held it in 26 quarters.
- Simplex Trading's Myriad Genetics position peaked at $1.14M in Q2 2017.
- 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.
Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.